IP Library › Granted Patent US 8,834,884
Granted Patent B2
US 8,834,884 · App. 13/924,776 · Granted Sep 16, 2014

Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier

Inventors: John T. Trogden (Villa Park, CA); Robert T. Lyons (Laguna Hills, CA)
Assignee: Allergan, Inc.
A61K9/0002A61K48/0075A61K9/0051A61K9/1617A61K47/10A61K9/1641A61K31/711A61K48/0008A61K9/1647A61K9/19A61K39/3955
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,834,884
App. No.
13/924,776
Granted
Sep 16, 2014
Kind
B2
Abstract

A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.

Claims (9)

1. A biodegradable sustained release intraocular drug delivery system in the form of microspheres for treating an ocular condition in a patient, the drug delivery system consisting of:

(a) a water soluble therapeutic agent,

(b) a polymeric carrier for the therapeutic agent, and

(c) a release modifier associated with the therapeutic agent to permit the therapeutic agent to be released into the interior of an eye of an individual for at least about one week after the drug delivery system is placed in the eye,

wherein the water soluble therapeutic agent is a protein, antibody, or antibody fragment,

wherein the polymeric carrier is a poly-lactic acid (PLA), a poly-lactide-co-glycolide (PLGA), or a mixture thereof, and

wherein the release modifier is 1-eicosanol.

2. A biodegradable sustained release intraocular drug delivery system according to claim 1 , wherein the water soluble therapeutic agent is an antibody.

3. A biodegradable sustained release intraocular drug delivery system according to claim 1 , wherein the water soluble therapeutic agent is an antibody selected from the group consisting of anti-VEGF antibodies and anti-VEGF receptor antibodies.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2014
From: TROGDEN, JOHN T.; LYONS, ROBERT T.
To: ALLERGAN, INC.
Reel/Frame 033077/0342 →
Continuity (4)
Continuation 13649339 · Oct 11, 2012
Continuation 13230355 · Sep 12, 2011
Continuation 11556503 · Nov 3, 2006
Related Publication 20130280272A1 · Oct 24, 2013